Startups
Ascilion’s proprietary microneedle technology makes access to molecular biomarkers quick, reliable, and comfortable. Our sampling platform can be tailored towards virtually any analytical or sensor technology used within products intended for spot measurement or wearables.
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 22, 2024 | Ascilion announces enrollment of first patient in DIGIPREDICT-Bio-DE study | The first patient has been enrolled in the DIGIPREDICT-Bio-DE study utilizing Ascilion technology at Deutsches Herzzentrum der Charité in Berlin STOCKHOLM, SWEDEN, April 22, 2024 /EINPresswire.com/ -- Ascilion AB ("Ascilion") the ... |
| Apr 18, 2024 | Ascilion technology judged top 1% of EU funded Innovations | Ascilion’s rating signals both the commercial potential and maturity of it's sampling technology. STOCKHOLM, SWEDEN, April 18, 2024 /EINPresswire.com/ -- Ascilion AB ("Ascilion") the leader in dermal interstitial fluid sampli... |
| Ascilion | “Sampling of dermal Interstitial Fluid (dISF) – Pioneering Hollow Microneedles – Ascilion designs, develops, and manufactures products based on hollow microneedles for sampling of dermal interstitial fluid (dISF). Access to endogenous and e... |
Reviews 0
FAQ about Ascilion
What has the press written about Ascilion?
Parsers VC has collected 4 articles mentioning Ascilion, among them “Ascilion announces enrollment of first patient in DIGIPREDICT-Bio-DE study” (Apr 22, 2024) and “Ascilion technology judged top 1% of EU funded Innovations” (Apr 18, 2024).
Is Ascilion still active?
Yes, Ascilion is active; its latest activity on Parsers VC dates from Mar 31, 2025.